Eli Lilly (LLY) Non-Current Deferred Tax Liability (2009 - 2022)

Eli Lilly (LLY) has 11 years of Non-Current Deferred Tax Liability data on file, last reported at $4.6 billion in Q4 2022.

• For the quarter ending Q4 2022, Non-Current Deferred Tax Liability rose 164.12% year-over-year to $4.6 billion; the trailing twelve-month figure through Dec 2022 stood at $4.6 billion (up 164.12% YoY), and the FY2022 full-year result was $4.6 billion, up 164.12% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2022 stood at $4.6 billion, up from $171.9 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $5.1 billion in Q4 2020 and bottomed at $171.9 million in Q3 2022.
• The 5-year median for Non-Current Deferred Tax Liability is $2.2 billion (2020), against an average of $2.4 billion.
• Peak annual rise in Non-Current Deferred Tax Liability reached 164.12% in 2022, while the deepest fall reached 89.47% in 2022.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $3.0 billion in 2018, then jumped by 51.61% to $4.6 billion in 2019, then advanced by 10.13% to $5.1 billion in 2020, then tumbled by 65.81% to $1.7 billion in 2021, then surged by 164.12% to $4.6 billion in 2022.
• The last three Non-Current Deferred Tax Liability figures came in at $4.6 billion (Q4 2022), $171.9 million (Q3 2022), and $862.5 million (Q2 2022), per Business Quant data.

Peer Comparison